Related references
Note: Only part of the references are listed.Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein
Stella Hernandez Maganhi et al.
PROTEIN SCIENCE (2017)
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
Peng Wu et al.
DRUG DISCOVERY TODAY (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Panel docking of small-molecule libraries - Prospects to improve efficiency of lead compound discovery
Pakornwit Sarnpitak et al.
BIOTECHNOLOGY ADVANCES (2015)
Extending kinome coverage by analysis of kinase inhibitor broad profiling data
Edgar Jacoby et al.
DRUG DISCOVERY TODAY (2015)
The ins and outs of selective kinase inhibitor development
Susanne Mueller et al.
NATURE CHEMICAL BIOLOGY (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Comprehensive Analysis of Three-Dimensional Activity Cliffs Formed by Kinase Inhibitors with Different Binding Modes and Cliff Mapping of Structural Analogues
Norbert Furtmann et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
Zheng Zhao et al.
ACS CHEMICAL BIOLOGY (2014)
A theoretical study of the structure and protonation of Palbociclib (PD 0332991)
Ibon Alkorta et al.
JOURNAL OF MOLECULAR STRUCTURE (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Blockbuster dreams for Pfizer's CDK inhibitor
Malini Guha
NATURE BIOTECHNOLOGY (2013)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
Current Status of Src Inhibitors in Solid Tumor Malignancies
Lauren N. Puls et al.
ONCOLOGIST (2011)
Proteus in the World of Proteins: Conformational Changes in Protein Kinases
Matthias Rabiller et al.
ARCHIV DER PHARMAZIE (2010)
Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis
Danzhi Huang et al.
BIOINFORMATICS (2010)
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
K. H. T. Paraiso et al.
BRITISH JOURNAL OF CANCER (2010)
Mitochondrial Hsp90 chaperones as novel molecular targets in prostate cancer
Dario C. Altieri
FUTURE ONCOLOGY (2010)
The (un)targeted cancer kinome
Oleg Fedorov et al.
NATURE CHEMICAL BIOLOGY (2010)
Targeting the cancer kinome through polypharmacology
Zachary A. Knight et al.
NATURE REVIEWS CANCER (2010)
Quantum chemical study of some cyclic nitrogen compounds as corrosion inhibitors of steel in NaCl media
Goekhan Gece et al.
CORROSION SCIENCE (2009)
Binding Site Similarity Analysis for the Functional Classification of the Protein Kinase Family
Sarah L. Kinnings et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
A pharmacophore map of small molecule protein kinase inhibitors
Malcolm J. McGregor
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2007)
Mechanisms of specificity in protein phosphorylation (vol 8, pg 530, 2007)
Jeffrey A. Ubersax et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Mechanisms of specificity in protein phosphorylation
Jeffrey A. Ubersax et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors
Jeffrey Jie-Lou Liao
JOURNAL OF MEDICINAL CHEMISTRY (2007)
MolDock: A new technique for high-accuracy molecular docking
Rene Thomsen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Mechanisms of disease - Chronic myeloid leukemia - Advances in biology and new approaches to treatment
JM Goldman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
Protein kinases - the major drug targets of the twenty-first century?
P Cohen
NATURE REVIEWS DRUG DISCOVERY (2002)
Structural aspects of protein kinase control - role of conformational flexibility
RA Engh et al.
PHARMACOLOGY & THERAPEUTICS (2002)
The Protein Data Bank and the challenge of structural genomics
HM Berman et al.
NATURE STRUCTURAL BIOLOGY (2000)
Share Paper
